Affimed Announces Listing Transfer to Nasdaq Capital Markets
04 oct. 2023 06h30 HE
|
Affimed N.V.
MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
27 sept. 2023 09h05 HE
|
Affimed N.V.
MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed to Present at the Cantor Global Healthcare Conference 2023
21 sept. 2023 06h30 HE
|
Affimed N.V.
MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
12 sept. 2023 06h30 HE
|
Affimed N.V.
AFM13 in combination with AlloNK® (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the...
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
07 sept. 2023 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
22 août 2023 05h00 HE
|
Affimed N.V.
By coupling the chromatography method FcRn-HPLC to a pH monitor, an optimized FcRn-pH-HPLC methodology was developed allowing correlation of antibodies’ serum half-life with FcRn column dissociation...
Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
10 août 2023 06h30 HE
|
Affimed N.V.
AFM13 combination with AB-101 NK cells (LuminICE-203): On track to report initial efficacy and safety data in the first half 2024; Type C meeting request submitted to FDA to clarify requirements for...
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
03 août 2023 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
31 juil. 2023 17h05 HE
|
Affimed N.V.
Stable disease was observed in three out of seven heavily pretreated patientsNo dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 (GLOBE NEWSWIRE)...
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
22 juin 2023 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...